Single high-dose antifungal plus HIV treatment for talaromycosis
Treatments studied
Part of Infections clinical trials.
This trial tests a one-time high dose of an antifungal medicine (liposomal amphotericin B) combined with a standard HIV treatment (B/F/TAF) for people with HIV who also have talaromycosis, a serious fungal infection. The goal is to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have HIV and have not yet started HIV treatment (ART).
- You have a confirmed diagnosis of talaromycosis (a fungal infection).
- You are not pregnant or breastfeeding.
- You do not have the infection in your brain or spinal cord.
- You do not have severe liver or kidney problems, or very low white blood cell counts.
- You have not been treated for talaromycosis for more than 48 hours before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two antifungal medicines to treat talaromycosis, a serious fungal infection common in people with HIV. It tests whether a shorter course of treatment with two medicines is as good as the standard approach, which may help reduce side effects and hospital time.
This study tests whether a one-time antifungal treatment can help people with HIV who have a positive cryptococcal antigen blood test but no symptoms. It may lower the chance that this infection becomes a serious illness affecting the brain.
This Phase 3 trial tests whether a high-dose form of amphotericin B made in tiny fat particles (liposomal amphotericin B) is safer and more effective for treating widespread Histoplasmosis in adults with HIV. It may help people who have a serious, whole-body infection caused by Histoplasma.
This trial is testing new treatments for cryptococcal meningitis, a serious brain infection, in people living with HIV. It aims to find the best way to treat this infection with fewer side effects.
This trial tests whether amphotericin B can treat new fungal infections that develop in people with blood cancers even after they have taken preventive antifungal medicine. It may help patients who have a confirmed or suspected fungal infection while on that prevention.
This study follows children and teens with blood cancers who got a fungal infection while on preventive antifungal medicine. It looks at how well liposomal amphotericin B (AmBisome) works and how safe it is for them.
Hear when a new HIV/AIDS-associated Talaromycosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.